Bone Therapeutics is collaborating with Kasios for two years to develop a new spinal fusion product.
Here are five things to know about the collaboration and new product:
1. The product will combine Bone Therapeutics' allogeneic osteoblastic cell therapy product ALLOB with Kasio's synthetic micro-granules bone substitute.
2. The project is subsidized by the government of the Walloon Region.
3. The two companies hope to offer a new approach to spinal fusion that will include:
• Osteoconduction
• Osteoinduction
• Osteogenesis
4. The combination of the ALLOB cells, which have already shown bone forming properties including osteoinduction and osteogenicity, with Kasios TCP's osteoconductive micro-granules could enhance three-dimensional growth and bone growth in spinal fusion.
5. The technology could be particularly helpful in promoting osteoconduction for larger fracture areas that need more structural support.